JPH054375B2 - - Google Patents
Info
- Publication number
- JPH054375B2 JPH054375B2 JP63201093A JP20109388A JPH054375B2 JP H054375 B2 JPH054375 B2 JP H054375B2 JP 63201093 A JP63201093 A JP 63201093A JP 20109388 A JP20109388 A JP 20109388A JP H054375 B2 JPH054375 B2 JP H054375B2
- Authority
- JP
- Japan
- Prior art keywords
- genus
- substance
- teratogenic
- agent according
- abnormalities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000005856 abnormality Effects 0.000 claims description 20
- 230000001080 anti-teratogenic effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000003439 teratogenic agent Substances 0.000 claims description 12
- 206010043275 Teratogenicity Diseases 0.000 claims description 10
- 231100000211 teratogenicity Toxicity 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 241000221198 Basidiomycota Species 0.000 claims description 9
- 241000233866 Fungi Species 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 240000006499 Flammulina velutipes Species 0.000 claims description 5
- 235000016640 Flammulina velutipes Nutrition 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000008722 morphological abnormality Effects 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002023 wood Substances 0.000 claims description 4
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- 238000000862 absorption spectrum Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 238000000921 elemental analysis Methods 0.000 claims description 2
- 238000001641 gel filtration chromatography Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 239000000126 substance Substances 0.000 description 47
- 238000000605 extraction Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 8
- 229960004630 chlorambucil Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 7
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 7
- 229960002756 azacitidine Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 230000000877 morphologic effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003192 teratological effect Effects 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000003390 teratogenic effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036244 malformation Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 241000019462 Colpodium versicolor Species 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 244000111056 Chinese albizia Species 0.000 description 1
- 241000272198 Ciconia Species 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000288902 Lemur catta Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006335 response to radiation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63201093A JPH0249732A (ja) | 1988-08-12 | 1988-08-12 | 抗催奇形性剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63201093A JPH0249732A (ja) | 1988-08-12 | 1988-08-12 | 抗催奇形性剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0249732A JPH0249732A (ja) | 1990-02-20 |
| JPH054375B2 true JPH054375B2 (enrdf_load_stackoverflow) | 1993-01-19 |
Family
ID=16435282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63201093A Granted JPH0249732A (ja) | 1988-08-12 | 1988-08-12 | 抗催奇形性剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0249732A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001242761A1 (en) * | 2000-03-24 | 2001-10-03 | Orient Cancer Therapy Co., Ltd. | Anticancer compositions |
-
1988
- 1988-08-12 JP JP63201093A patent/JPH0249732A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0249732A (ja) | 1990-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH08500589A (ja) | アストラガルス ポリサッカライド免疫調節剤 | |
| JPH09238697A (ja) | マイタケから抽出した抗腫瘍物質 | |
| US6660722B2 (en) | Therapeutical treatments | |
| CS219880B2 (en) | Method of isolation of the polysaccharide | |
| JP3444624B2 (ja) | 高分岐度β−グルカン、その製造法及び用途 | |
| SU704431A3 (ru) | Способ получени полисахаридов, обладающих противоопухолевым действием | |
| US6726932B2 (en) | Fatty acid-containing composition | |
| JPH0539305A (ja) | アストラガルス・メンブラナセウスから抽出した免疫 変調性多糖類及びこれらを含有する薬剤組成物 | |
| EP0001945A1 (fr) | Nouveaux polysaccharides extraits de corps microbiens d'Haemophilus Influenzae, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
| EP0382551B1 (en) | Prevention and treatment of herpes virus infections | |
| KR920002935B1 (ko) | 맥관 형성 저해제 | |
| JP4233029B2 (ja) | マイタケ由来の抽出物およびグリコプロテイン並びにその製造方法 | |
| JPH054375B2 (enrdf_load_stackoverflow) | ||
| US6015796A (en) | Method for treating AIDS | |
| JP4421684B2 (ja) | 肥満防止剤及びその製造法 | |
| JP2007031665A (ja) | マイタケから抽出した糖―タンパク複合体 | |
| CN100532395C (zh) | 一种源自灰树花子实体的α-葡聚糖、其制备方法及用途 | |
| JP4480204B2 (ja) | カワリハラタケの抗腫瘍性画分 | |
| JPH0248000B2 (enrdf_load_stackoverflow) | ||
| JPS6152807B2 (enrdf_load_stackoverflow) | ||
| JPH07238031A (ja) | 血糖上昇抑制剤 | |
| JPH042574B2 (enrdf_load_stackoverflow) | ||
| JPS6213327B2 (enrdf_load_stackoverflow) | ||
| KR810001499B1 (ko) | 질소를 함유하는 다당류의 제조방법 | |
| KR20010102264A (ko) | 항-ｈｉｖ제 |